News|Articles|November 16, 2026

Ascletis Submits FDA IND for ASC30_39 Oral Obesity Combination

Fact checked by: Abigail Brooks, MA

Ascletis submits an FDA IND for ASC30_39, an oral GLP-1–amylin obesity combination supported by preclinical data.

Ascletis has submitted an investigational new drug (IND) application to the US Food and Drug Administration for ASC30_39 FDC, a once-daily oral fixed-dose combination of a glucagon-like peptide-1 receptor (GLP-1R) agonist and a selective amylin receptor agonist for obesity. The submission concerns a combination tablet supported by preclinical findings; the announcement does not report human efficacy or safety results for the co-formulation.¹

The tablet combines ASC30, an oral small-molecule GLP-1R agonist, with ASC39, an oral small-molecule selective amylin receptor agonist. Ascletis describes the product as the first oral GLP-1–amylin co-formulation to reach IND submission, a development milestone rather than evidence of clinical benefit.¹

“ASC30_39 FDC is the first co-formulation of an oral GLP-1 and an oral amylin to reach IND submission, combining two validated, complementary mechanisms for weight management in a single once-daily tablet,” said Jinzi Jason Wu, PhD, founder, chairman, and CEO of Ascletis. Whether this pairing provides additional weight reduction or acceptable tolerability in patients remains unanswered by the reported findings.¹

Preclinical Findings Support Combination Development

According to Ascletis, oral administration of ASC30_39 FDC in dogs produced a half-life of up to 12 hours. The company described oral bioavailability and drug exposure favorably but provided no numerical values for those measures in the announcement. Pharmacokinetic parameters were reportedly consistent with those of the individual agents in a head-to-head dog study.¹

Key Facts

  • Drug: ASC30_39 FDC
  • Class: GLP-1R/amylin receptor agonists
  • Proposed indication: Obesity
  • Action: US FDA IND application submitted
  • Efficacy: No human combination results reported
  • Safety: No combination safety rates reported
  • Status: Investigational; US submission

Ascletis also reported compatibility between the components, room-temperature stability, and a small tablet size. These formulation characteristics may be relevant to product development, but the release provides no patient adherence or treatment-persistence data. The animal pharmacokinetic findings do not establish once-daily exposure or an effective dose in humans.¹

For ASC39 alone, the company reported 40-fold selectivity for the human amylin 1 receptor over the human calcitonin receptor. In diet-induced obese rats, 6 consecutive days of once-daily oral administration produced a 6.6% placebo-adjusted body-weight reduction, compared with 5.6% for eloralintide. These are preclinical results, not estimates of weight loss patients can expect.¹

Human Evidence Remains Component-Specific

ASC30 is being evaluated in 2 global pivotal phase 3 trials, AURORA-1 and AURORA-2. According to Ascletis, the program is enrolling approximately 4600 participants with obesity or overweight across the US, Europe, and Canada. Topline results are expected in the third quarter of 2028. These studies concern ASC30, not the fixed-dose combination.¹

The company also cited a vomiting rate with ASC30 approximately half that reported for orforglipron when both drugs used weekly titration in separate studies. This non–head-to-head comparison cannot establish superior gastrointestinal tolerability. The announcement supplies no corresponding combination safety results, adverse-event rates, or discontinuation data. Ascletis separately reported submitting a US IND application for ASC39.¹

Clinical Questions and Next Steps

For clinicians, the principal question is whether combining these receptor targets in one oral tablet can deliver meaningful weight reduction with manageable adverse effects. The announcement does not establish the combination’s place relative to existing obesity treatments.¹

The reported regulatory action is an IND submission—not marketing approval. The release does not report FDA clearance to begin the combination study, a clinical trial protocol, planned enrollment, dosing, or endpoints. Human dose-finding, efficacy, and safety results will be necessary to assess the co-formulation; longer-term ASC30 findings will not independently resolve those questions.¹

References

  1. Ascletis Pharma Inc. Ascletis submits IND application to the U.S. FDA for ASC30_39 FDC, a potentially first-in-class oral small molecule fixed-dose combination of GLP-1R agonist and selective amylin receptor agonist, for the treatment of obesity. PR Newswire. November 11, 2026. https://www.prnewswire.com/news-releases/ascletis-submits-ind-application-to-the-us-fda-for-asc3039-fdc-a-potentially-first-in-class-oral-small-molecule-fixed-dose-combination-of-glp-1r-agonist-and-selective-amylin-receptor-agonist-for-the-treatment-of-obesity-302935882.html

Related to this article